Exforge医学信息.ppt

内 容 1、我国高血压治疗现状 2、联合治疗，降压达标——众多指南推荐 3、优选的联合治疗 机制协同，增强降压疗效 更强的心血管保护 不良事件减少 内 容 1、我国高血压治疗现状 2、联合治疗，降压达标——众多指南推荐 3、优选的联合治疗 机制协同，增强降压疗效 更强的心血管保护 不良事件减少 内 容 1、我国高血压治疗现状 2、联合治疗，降压达标——众多指南推荐 3、优选的联合治疗 机制协同，增强降压疗效 更强的心血管保护 不良事件减少 * ACCOMPLISH证实了在心血管保护方面，RASI/CCB单片复方制剂优于RASI/HCTZ单片复方制剂。 * * Amlodipine has been widely studied in large morbidity and mortality outcomes trials, such as PREVENT, CAMELOT, ASCOT-BPLA/CAFE AND ALLHAT. This slide shows the results for the primary outcome and selected secondary outcomes in these trials. Abbreviations: PREVENT = Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial CAMELOT = Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis ASCOT-BPLA = Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm CAFE = Conduit Artery Function Evaluation Study ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial * 缬沙坦 has been extensively studied during the past few years in a mega-trials program involving approximately 50,000 patients, larger than any other angiotensin receptor blocker trial program. Completed trials have investigated the influence of 缬沙坦 on morbidity and mortality in patients with post-myocardial infarction, heart failure as well as in patients at high cardiovascular (CV) risk. In addition, trials have examined 缬沙坦 in patients with specific risk factors for CV disease such as microalbuminuria and type 2 diabetes mellitus. The ongoing program extends the clinical observations to potential prevention of type 2 diabetes mellitus and/or a reduction in CV events in high-risk patients with impaired glucose tolerance. * Valsartan has been widely studied in large morbidity and mortality outcomes trials, such as VALUE, VALIANT, Val-HeFT and more recently the Jikei Heart Study in a range of patients including high-risk hypertensives, post-myocardial infarction patients and heart failur